Master Samip, Leary Cheri, Takalkar Amol, Coltelingam James, Mansour Richard, Mills Glenn M, Koshy Nebu
Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
Case Rep Oncol. 2017 Jun 19;10(2):534-541. doi: 10.1159/000477338. eCollection 2017 May-Aug.
Patients with chronic lymphocytic leukemia (CLL) who progress to Richter transformation (RT) have a poor prognosis. Multi-agent chemotherapy regimens do not have good response rates. There are few case reports on the use of ibrutinib in RT. Here, we present a patient who was heavily pretreated for CLL, including allogeneic stem cell transplant, and progressed to RT. She had a mixed response to multi-agent chemotherapy and was started on ibrutinib. She had a complete response for 16 months on single-agent ibrutinib with minimal toxicity.
进展为Richter转化(RT)的慢性淋巴细胞白血病(CLL)患者预后较差。多药化疗方案的缓解率不佳。关于伊布替尼在RT中的应用仅有少数病例报告。在此,我们报告一名曾接受包括异基因干细胞移植在内的多种CLL预处理方案且进展为RT的患者。她对多药化疗反应不一,随后开始使用伊布替尼。她单药使用伊布替尼16个月,达到完全缓解,且毒性极小。